Healthcare / Drug Manufacturers - GeneralNYSE
$54.95
-2.23 (-3.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $12.8B · quality 62.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$112.2B
P/E
15.4x
↓EV/EBITDA
9.8x
↓ROE
38.2%
↑Gross Margin
71.1%
↑Debt/Equity
2.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+6.5%
FCF CAGR
+10.0%
FCF margin
26.7%
FCF / Net income
1.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48.20B · net income $7.05B · FCF $12.85B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $48.20B | $48.20B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | $16.39B | $17.62B | $21.24B | $19.48B | $18.81B | $17.71B | $15.62B |
| Net Income | $7.05B | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | $2.56B | $1.96B | $3.71B | $3.10B | $10.61B | $5.25B | $2.17B |
| EBITDA | $15.23B | $15.23B | $3.17B | $19.37B | $19.22B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 3.46 | 3.46 | -4.41 | 3.86 | 2.95 | 3.12 | -3.99 | 2.01 | 3.01 | 0.61 | 2.65 | 0.93 | 1.20 | 1.54 | 1.16 | 2.16 | 1.79 | 5.34 | 2.62 | 1.09 |
| Gross Margin | 71.1% | 71.1% | 71.1% | 76.2% | 78.0% | — | 72.3% | 69.1% | 71.3% | 70.7% | 74.5% | 76.4% | 75.2% | 71.8% | 73.8% | 73.6% | 72.9% | 72.7% | — | — |
| Operating Margin | 28.5% | 28.5% | 12.2% | 18.2% | 19.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | 14.6% | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.8% | 22.9% | 9.5% | 12.6% | 15.6% | 11.1% | 17.5% | 15.9% | 56.4% | 29.6% | 13.9% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 2.55 | 2.55 | 3.13 | 1.41 | 1.31 | 1.10 | 1.28 | 0.84 | 0.40 | 0.59 | 0.35 | 0.46 | 0.49 | 0.53 | 0.48 | 0.34 | 0.34 | 0.41 | 0.54 | — |
| Current Ratio | 1.42 | 1.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $12.85B | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.37B | $6.12B | $4.22B | $1.84B | $1.28B | $2.62B | $3.01B | $6.39B | $4.47B | $4.07B | $3.33B | $2.77B | $2.31B |
| Returns | ||||||||||||||||||||
| ROE | 38.2% | 38.2% | -54.8% | 27.3% | 20.4% | 19.5% | -23.8% | 6.7% | 35.1% | 8.6% | 27.6% | 11.0% | 13.5% | 16.9% | 14.4% | 23.2% | 19.7% | 71.5% | 42.9% | — |
| Valuation | ||||||||||||||||||||
| P/E | 15.39 | 15.39 | — | 13.53 | 24.75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 9.78 | 9.78 | 49.09 | 7.15 | 9.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 6.07 | 6.07 | 7.02 | 3.69 | 5.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | -0.2% | -0.2% | 7.3% | -2.5% | — | 9.1% | 62.6% | 15.9% | 8.6% | 6.9% | 17.3% | 4.3% | -3.1% | -7.0% | -17.1% | 9.0% | 3.6% | 6.2% | 13.4% | — |
| EPS Growth | 178.5% | 178.5% | -214.2% | 30.8% | — | 178.2% | -298.5% | -33.2% | 393.4% | -77.0% | 184.9% | -22.5% | -22.1% | 32.8% | -46.3% | 20.7% | -66.5% | 103.8% | 140.4% | — |
| Dividend Yield | 4.6% | 4.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
12.1%
EPS terminal req.
$4.88
Spread vs growth
166.3%
5Y implied EPS CAGR
11.3%
EPS terminal req.
$5.90
Spread vs growth
167.2%
10Y implied EPS CAGR
10.6%
EPS terminal req.
$9.50
Spread vs growth
167.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+18.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.41 → 3.46
Residual
+13.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.